Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals
Authors:
- Ana Sandoval-RodríguezASAna Sandoval-Rodríguez
- Mayra Mena-EnriquezMMMayra Mena-Enriquez
- Jesús García-BañuelosJesús García-Bañuelos
- Adriana Salazar-MontesASAdriana Salazar-Montes
- Mary Fafutis-MorrisMFMary Fafutis-Morris
- Monica Vázquez-Del MercadoMMMonica Vázquez-Del Mercado
- Arturo Santos-GarcíaASArturo Santos-García
- Juan Armendariz-BorundaJAJuan Armendariz-Borunda
- 6 March 2020
- journal article
- research article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 62 (4) , 260-272
Abstract
Pre-existing immune response against adenovirus could diminish transgene expression efficiency when Ad is employed in humans as gene therapy vector. We previously used Ad-hΔuPA (Recombinant adenovirus expressing human urokinase-type plasminogen activator) as antifibrotic gene therapy in cirrhosis models and demonstrated its effectiveness. As a further clinical approach, transient Cyclosporine A (CsA) immunosuppression was induced in cirrhotic animals to determine whether Ad-hΔuPA administration retained efficacy. Adenovirus sensitization was achieved by systemic administration of non-therapeutic Ad-βGal (Recombinant adenovirus expressing beta-galactosidase) after 4 weeks of intraperitoneal carbon tetrachloride (CCl4) regimen. Cirrhosis induction continued up to 8 weeks. At the end of CCl4 intoxication, immunosuppression was achieved with three CsA doses (40 mg/kg) as follows: 24 h before administration of Ad-hΔuPA, at the moment of Ad-hΔuPA injection and finally, 24 h after Ad-hΔuPA inoculation. At 2 and 72 h after Ad-hΔuPA injection, animals were sacrificed. Liver, spleen, lung, kidney, heart, brain, and testis were analyzed for Ad-biodistribution and transgene expression. In naïve animals, Ad-hΔuPA genomes prevailed in liver and spleen, while Ad-sensitized rats showed Ad genomes also in their kidney and heart. Cirrhosis and Ad preimmunization status notably diminished transgene liver expression compared to healthy livers. CsA immunosuppression in cirrhotic animals has no effect on Ad-hΔuPA biodistribution, but increments survival.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (259096, 103772)
This publication has 42 references indexed in Scilit:
- Production of first generation adenoviral vectors for preclinical protocols: Amplification, purification and functional titrationJournal of Bioscience and Bioengineering, 2011
- Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal EndotheliumPLOS Pathogens, 2011
- Improving Adenovirus Based Gene Transfer: Strategies to Accomplish Immune EvasionViruses, 2010
- Intensive Pharmacological Immunosuppression Allows for Repetitive Liver Gene Transfer With Recombinant Adenovirus in Nonhuman PrimatesMolecular Therapy, 2010
- Strategies to Modulate Immune Responses: A New Frontier for Gene TherapyMolecular Therapy, 2009
- Biodistribution of Radioiodinated Adenovirus Fiber Protein Knob Domain after Intravenous Injection in MiceJournal of Virology, 2004
- A Hemodynamic Response to Intravenous Adenovirus Vector Particles Is Caused by Systemic Kupffer Cell-Mediated Activation of Endothelial CellsHuman Gene Therapy, 2003
- Preexisting Antiadenoviral Immunity Is Not a Barrier to Efficient and Stable Transduction of the Brain, Mediated by Novel High-Capacity Adenovirus VectorsHuman Gene Therapy, 2001
- FK506 Immunosuppression to Control the Immune Reactions Triggered by First-Generation Adenovirus-Mediated Gene TransferHuman Gene Therapy, 1995
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995